Search

Your search keyword '"Dent S"' showing total 503 results
Start Over Author "Dent S"
503 results on '"Dent S"'

1. Trying to Solve the 'Worst Situation' Together: Participatory Autism Research

Author

Costley, D.M, Emerson, A., Ropar, D., Sheppard, E., McCubbing, A., Campbell Bass, S., Dent, S., Ellis, R., Limer, S., Phillips, S., and Ward Penny, J.

Abstract

The importance of participatory autism research is discussed in relation to a project involving six autistic researchers and five non-autistic university researchers collaborating to investigate anxiety in autistic adolescents. The paper describes the process of establishing a research partnership and the values and philosophy behind this inclusive method of research. Lessons were learnt about neurodivergent thinking and the benefits it brings to the development of research questions and analysis of data.

Published
2023
Full Text
View/download PDF

2. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

Author

Curigliano, G, Lenihan, D, Fradley, M, Ganatra, S, Barac, A, Blaes, A, Herrmann, J, Porter, C, Lyon, A, Lancellotti, P, Patel, A, DeCara, J, Mitchell, J, Harrison, E, Moslehi, J, Witteles, R, Calabro, M, Orecchia, R, de Azambuja, E, Zamorano, J, Krone, R, Iakobishvili, Z, Carver, J, Armenian, S, Ky, B, Cardinale, D, Cipolla, C, Dent, S, and Jordan, K

Subjects
Clinical Practice Guidelines, cardiac disease, cardiovascular toxicity, diagnosis, recommendations, Humans, Antineoplastic Agents, Consensus, Heart Diseases, Medical Oncology, Neoplasms
Abstract

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

Published
2020

6. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

Author

Lyon, A. R., Lopez-Fernandez, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., Cutter, D. J., de Azambuja, E., de Boer, R. A., Dent, S. F., Farmakis, D., Gevaert, S. A., Gorog, D. A., Herrmann, J., Lenihan, D., Moslehi, J., Moura, B., Salinger, S. S., Stephens, R., Suter, T. M., Szmit, S., Tamargo, J., Thavendiranathan, P., Tocchetti, C. G., van der Meer, P., van der Pal, H. J. H., Lancellotti, P., Thuny, F., Abdelhamid, M., Aboyans, V., Aleman, B., Alexandre, J., Barac, A., Borger, M. A., Casado-Arroyo, R., Cautela, J., Celutkiene, J., Cikes, M., Cohen-Solal, A., Dhiman, K., Ederhy, S., Edvardsen, T., Fauchier, L., Fradley, M., Grapsa, J., Halvorsen, S., Heuser, M., Humbert, M., Jaarsma, T., Kahan, T., Konradi, A., Koskinas, K. C., Kotecha, D., Ky, B., Landmesser, U., Lewis, B. S., Linhart, A., Lip, G. Y. H., Lochen, M. -L., Malaczynska-Rajpold, K., Metra, M., Mindham, R., Moonen, M., Neilan, T. G., Nielsen, J. C., Petronio, A. -S., Prescott, E., Rakisheva, A., Salem, J. -E., Savarese, G., Sitges, M., Ten Berg, J., Touyz, R. M., Tycinska, A., Wilhelm, M., Zamorano, J. L., Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Group, ESC Scientific Document, Lyon, Alexander R, López-Fernández, Teresa, Couch, Liam S, Asteggiano, Riccardo, Aznar, Marianne C, Bergler-Klein, Jutta, Boriani, Giuseppe, Cardinale, Daniela, Cordoba, Raul, Cosyns, Bernard, Cutter, David J, de Azambuja, Evandro, de Boer, Rudolf A, Dent, Susan F, Farmakis, Dimitrio, Gevaert, Sofie A, Gorog, Diana A, Herrmann, Joerg, Lenihan, Daniel, Moslehi, Javid, Moura, Brenda, Salinger, Sonja S, Stephens, Richard, Suter, Thomas M, Szmit, Sebastian, Tamargo, Juan, Thavendiranathan, Paaladinesh, Tocchetti, Carlo G, van der Meer, Peter, van der Pal, Helena J H, Cardiology, Clinical sciences, and Cardio-vascular diseases

Subjects
Cardiac magnetic resonance, Cancer survivors, Vascular endothelial growth factor inhibitors (VEGFi), Myocarditi, Guideline, Anthracycline, Arrhythmias, Medical Oncology, T-CELL THERAPY, Coronary artery disease, Strain, RECURRENT VENOUS THROMBOEMBOLISM, Amyloid light-chain cardiac amyloidosis, Androgen deprivation therapy, Atrial fibrillation, Biomarkers, Cancer, Carcinoid syndrome, Cardiac tumour, Cardio-oncology, Cardiotoxicity, Chemotherapy, Echocardiography, Fluoropyrimidine, Guidelines, Haematopoietic stem cell transplantation, Heart failure, Hormone therapy, Hypertension, Immunotherapy, Ischaemic heart disease, Myocarditis, Pericardial disease, Proteasome inhibitors, Pulmonary hypertension, QTc prolongation, Radiotherapy, Risk stratification, Thrombosis, Trastuzumab, Valvular heart disease, Venous thromboembolism, Neoplasms, Proteasome inhibitor, Amyloid light-chain cardiac amyloidosi, IMMUNE CHECKPOINT INHIBITORS, Cardiotoxicity/diagnostic imaging, Heart, General Medicine, Hematology, MOLECULAR-WEIGHT HEPARIN, BRAIN NATRIURETIC PEPTIDE, oncology, Cancer survivor, Thrombosi, CORONARY-ARTERY-DISEASE, Cardiology and Cardiovascular Medicine, TYROSINE KINASE INHIBITOR, Arrhythmia, Neoplasms/diagnostic imaging, Antineoplastic Agents, Humans, Radiology, Nuclear Medicine and imaging, EARLY BREAST-CANCER, CARCINOID HEART-DISEASE, Antineoplastic Agents/therapeutic use, Biomarker, AORTIC-VALVE-REPLACEMENT, Radiation Oncology
Published
2022
Full Text
View/download PDF

11. List of Contributors

Author

AlBadri, A., primary, Almuwaqqat, Z., additional, Aseyev, O., additional, Asher, A., additional, Asier, S., additional, Biasillo, G., additional, Bronte, E., additional, Cahill, P.A., additional, Cardinale, D., additional, Carver, J., additional, Chandra, S., additional, Cipolla, C.M., additional, Dent, S., additional, Dhingra, R., additional, Dunhill, J., additional, El-Chami, M.F., additional, Engle, J., additional, Fisher, S., additional, Franco, V.I., additional, Galvano, A., additional, Geft, D., additional, Ghosh, N., additional, Gleason, P.T., additional, Gupta, D., additional, Hage, A., additional, Hamilton, M.A., additional, Hung, O., additional, Johl, M.M., additional, Johnson, C., additional, Kirshenbaum, L.A., additional, Kittleson, M.M., additional, Kransdorf, E.P., additional, Kumbla, R.A., additional, Lajoie, A., additional, Lally, C., additional, Law, A., additional, Lerakis, S., additional, Lipshultz, S.E., additional, Lisko, J.C., additional, Margulets, V., additional, Mehta, P.K., additional, Mita, M., additional, Motwani, M., additional, Moudgil, R., additional, Ng, A., additional, Novo, G., additional, Okwuosa, T.M., additional, Palomo, A., additional, Parashar, S., additional, Patel, N., additional, Redmond, E.M., additional, Russo, A., additional, Sarbaziha, R., additional, Sekhon, N., additional, Shiao, S.L., additional, Shufelt, C.L., additional, Silver, A., additional, Sittig, M.P., additional, Tamarappoo, B.K., additional, Tank, R.H., additional, Tejada, T., additional, Thomson, L.E.J., additional, Wall, D., additional, Wang, E.T., additional, Wei, J., additional, and Yeh, E.T.H., additional

Published
2017
Full Text
View/download PDF

14. Multimorbidity and quality of primary care after release from prison: a prospective data-linkage cohort study

Author

Calais-Ferreira, L, Butler, A, Dent, S, Preen, DB, Young, JT, Kinner, SA, Calais-Ferreira, L, Butler, A, Dent, S, Preen, DB, Young, JT, and Kinner, SA

Abstract

BACKGROUND: The period after release from prison can be challenging, especially due to a higher risk of morbidity and mortality despite commonly increased use of healthcare services. However, little is known about the quality of the healthcare offered to this population, which limits the possibility of addressing this important health inequity. This study characterised multimorbidity and investigated the relationship between multimorbidity and quality of primary healthcare in adults within 2 years after release from prison. METHODS: This was a prospective cohort study of 1046 participants of a service brokerage intervention after release from prison between August 2008 and July 2010 in Queensland, Australia. Participants had their baseline survey and clinical data linked prospectively with their medical, correctional and death records. Multimorbidity was ascertained using the Cumulative Illness Rating Scale and classified into three categories: none, moderate (morbidity in 2-3 domains) and complex (morbidity in 4 or more domains). Outcomes were Usual Provider Continuity Index (UPCI), Continuity of Care (COC) Index, and having at least one extended primary care consultation (> 20 minutes). Descriptive statistics and logistic regression were used in the analyses. RESULTS: Multimorbidity was present for 761 (73%) participants, being more prevalent among females (85%) than males (69%), p < 0.001. Moderate multimorbidity was not associated with UPCI or COC, but was associated with having at least one long consultation (AOR = 1.64; 95% CI:1.14-2.39), after adjusting for covariates. Complex multimorbidity was positively associated with all outcomes in the adjusted models. Indigenous status was negatively associated with UPCI (AOR = 0.54; 95% CI: 0.37-0.80) and COC (AOR = 0.53; 95% CI: 0.36-0.77), and people younger than 25 years were at 36% lower odds (AOR = 0.64; 95% CI: 0.44-0.93) of having a long consultation than the middle-aged group (25-44 years) in the adjusted mode

Published
2022

15. Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial

Author

Maurer, C., Agostinetto, E., Ameye, L., Lambertini, M., Martel, S., Ponde, N. F., Brandao, M., Poggio, F., Ferreira, A. R., Schiff, R., De Angelis, C., Gelber, R. D., Dent, S., Thomssen, C., Piccart, M., de Azambuja, E., Maurer, C., Agostinetto, E., Ameye, L., Lambertini, M., Martel, S., Ponde, N. F., Brandao, M., Poggio, F., Ferreira, A. R., Schiff, R., De Angelis, C., Gelber, R. D., Dent, S., Thomssen, C., Piccart, M., and de Azambuja, E.

Published
2022

17. 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial

Author

Maurer, C., primary, Agostinetto, E., additional, Ameye, L., additional, Lambertini, M., additional, Martel, S., additional, Ponde, N.F., additional, Brandão, M., additional, Poggio, F., additional, Ferreira, A.R., additional, Schiff, R., additional, De Angelis, C., additional, Gelber, R.D., additional, Dent, S., additional, Thomssen, C., additional, Piccart, M., additional, and de Azambuja, E., additional

Published
2022
Full Text
View/download PDF

23. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology

Author

Pudil, R. Mueller, C. Čelutkienė, J. Henriksen, P.A. Lenihan, D. Dent, S. Barac, A. Stanway, S. Moslehi, J. Suter, T.M. Ky, B. Štěrba, M. Cardinale, D. Cohen-Solal, A. Tocchetti, C.G. Farmakis, D. Bergler-Klein, J. Anker, M.S. Von Haehling, S. Belenkov, Y. Iakobishvili, Z. Maack, C. Ciardiello, F. Ruschitzka, F. Coats, A.J.S. Seferovic, P. Lainscak, M. Piepoli, M.F. Chioncel, O. Bax, J. Hulot, J.-S. Skouri, H. Hägler-Laube, E.S. Asteggiano, R. Fernandez, T.L. de Boer, R.A. Lyon, A.R.

Abstract

Serum biomarkers are an important tool in the baseline risk assessment and diagnosis of cardiovascular disease in cancer patients receiving cardiotoxic cancer treatments. Increases in cardiac biomarkers including cardiac troponin and natriuretic peptides can be used to guide initiation of cardioprotective treatments for cancer patients during treatment and to monitor the response to cardioprotective treatments, and they also offer prognostic value. This position statement examines the role of cardiac biomarkers in the management of cancer patients. The Cardio-Oncology Study Group of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the Cardio-Oncology Council of the ESC have evaluated the current evidence for the role of cardiovascular biomarkers in cancer patients before, during and after cardiotoxic cancer therapies. The characteristics of the main two biomarkers troponin and natriuretic peptides are discussed, the link to the mechanisms of cardiovascular toxicity, and the evidence for their clinical use in surveillance during and after anthracycline chemotherapy, trastuzumab and HER2-targeted therapies, vascular endothelial growth factor inhibitors, proteasome inhibitors, immune checkpoint inhibitors, cyclophosphamide and radiotherapy. Novel surveillance clinical pathways integrating cardiac biomarkers for cancer patients receiving anthracycline chemotherapy or trastuzumab biomarkers are presented and future direction in cardio-oncology biomarker research is discussed. © 2020 European Society of Cardiology

Published
2020

24. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

Author

Lyon, A.R. Dent, S. Stanway, S. Earl, H. Brezden-Masley, C. Cohen-Solal, A. Tocchetti, C.G. Moslehi, J.J. Groarke, J.D. Bergler-Klein, J. Khoo, V. Tan, L.L. Anker, M.S. von Haehling, S. Maack, C. Pudil, R. Barac, A. Thavendiranathan, P. Ky, B. Neilan, T.G. Belenkov, Y. Rosen, S.D. Iakobishvili, Z. Sverdlov, A.L. Hajjar, L.A. Macedo, A.V.S. Manisty, C. Ciardiello, F. Farmakis, D. de Boer, R.A. Skouri, H. Suter, T.M. Cardinale, D. Witteles, R.M. Fradley, M.G. Herrmann, J. Cornell, R.F. Wechelaker, A. Mauro, M.J. Milojkovic, D. de Lavallade, H. Ruschitzka, F. Coats, A.J.S. Seferovic, P.M. Chioncel, O. Thum, T. Bauersachs, J. Andres, M.S. Wright, D.J. López-Fernández, T. Plummer, C. Lenihan, D.

Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies. © 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Published
2020

25. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from theCardio-OncologyStudyGroup of theHeartFailureAssociation of theEuropeanSociety ofCardiology in collaboration with theInternationalCardio-OncologySociety

Author

Lyon, AR, Dent, S, Stanway, S, Earl, H, Brezden-Masley, C, Cohen-Solal, A, Tocchetti, CG, Moslehi, JJ, Groarke, JD, Bergler-Klein, J, Khoo, V, Tan, LL, Anker, MS, von Haehling, S, Maack, C, Pudil, R, Barac, A, Thavendiranathan, P, Ky, B, Neilan, TG, Belenkov, Y, Rosen, SD, Iakobishvili, Z, Sverdlov, AL, Hajjar, LA, Macedo, AVS, Manisty, C, Ciardiello, F, Farmakis, D, de Boer, RA, Skouri, H, Suter, TM, Cardinale, D, Witteles, RM, Fradley, MG, Herrmann, J, Cornell, RF, Wechelaker, A, Mauro, MJ, Milojkovic, D, de Lavallade, H, Ruschitzka, F, Coats, AJS, Seferovic, PM, Chioncel, O, Thum, T, Bauersachs, J, Andres, MS, Wright, DJ, Lopez-Fernandez, T, Plummer, C, Lenihan, D, Lyon, AR, Dent, S, Stanway, S, Earl, H, Brezden-Masley, C, Cohen-Solal, A, Tocchetti, CG, Moslehi, JJ, Groarke, JD, Bergler-Klein, J, Khoo, V, Tan, LL, Anker, MS, von Haehling, S, Maack, C, Pudil, R, Barac, A, Thavendiranathan, P, Ky, B, Neilan, TG, Belenkov, Y, Rosen, SD, Iakobishvili, Z, Sverdlov, AL, Hajjar, LA, Macedo, AVS, Manisty, C, Ciardiello, F, Farmakis, D, de Boer, RA, Skouri, H, Suter, TM, Cardinale, D, Witteles, RM, Fradley, MG, Herrmann, J, Cornell, RF, Wechelaker, A, Mauro, MJ, Milojkovic, D, de Lavallade, H, Ruschitzka, F, Coats, AJS, Seferovic, PM, Chioncel, O, Thum, T, Bauersachs, J, Andres, MS, Wright, DJ, Lopez-Fernandez, T, Plummer, C, and Lenihan, D

Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.

Published
2020

26. Intramyocardial fast-SENC is less impacted by compensatory mechanisms while monitoring cardiotoxic effects of chemotherapy than echocardiography and conventional CMR: the PREFECT study

Author

Steen, H, primary, Montenbruck, M, additional, Gersak, B, additional, Schwarz, A.K, additional, Esch, S, additional, Kelle, S, additional, Giusca, S, additional, Korosoglou, G, additional, Wuelfing, P, additional, Dent, S, additional, and Lenihan, D, additional

Published
2020
Full Text
View/download PDF

27. 3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with fulvestrant in oestrogen receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA-mutant advanced breast cancer

Author

Jacot, W., primary, Savage, H.M., additional, Dent, S., additional, Cortés, J., additional, Im, Y-H., additional, Dieras, V.C., additional, Harbeck, N., additional, Krop, I.E., additional, Chen, J., additional, Sokol, E., additional, Schimmoller, F., additional, Hsu, J., additional, De Laurentiis, M., additional, and Wilson, T.R., additional

Published
2020
Full Text
View/download PDF

33. Case 1

Author

Topham, E. J., Simpson Dent, S. L., and Child, F. J.

Published
2003

44. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)

Author

Zamorano, JL, Munoz, D, Aboyans, V, Asteggiano, R, Galderisi, M, Habib, G, Lenihan, DJ, Lip, GYH, Lyon, AR, Fernandez, TL, Mohty, D, Piepoli, MF, Tamargo, J, Torbicki, A, Suter, TM, Achenbach, S, Agewall, S, Badimon, L, Baron-Esquivias, G, Baumgartner, H, Bax, JJ, Bueno, H, Carerj, S, Dean, V, Gaemperli, O, Kirchhof, P, Kolh, P, Lancellotti, P, Nihoyannopoulos, P, Ponikowski, P, Roffi, M, Carneiro, AV, Windecker, S, Minotti, G, Cardinale, D, de Azambuja, E, Dent, S, Erol, C, Ewer, MS, Farmakis, D, Fietkau, R, Fitzsimons, D, McGale, P, and Ringwald, J

Subjects
cardio-oncology, myocardial dysfunction, cardiotoxicity, surveillance, cancer therapy, ischaemia, chemotherapy, early detection, arrhythmias, European Society of Cardiology
Published
2017

49. Abstract OT3-05-06: EarLEE-2: A phase 3 study of ribociclib + endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), intermediate-risk, early breast cancer (EBC)

Author

O'Shaughnessy, J, primary, Alba, E, additional, Bardia, A, additional, Dent, S, additional, Dieras, V, additional, Hortobagyi, G, additional, Im, S-A, additional, Montemurro, F, additional, Untch, M, additional, Yardley, DA, additional, Chakravartty, A, additional, Germa, C, additional, Miller, M, additional, and Slamon, D, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results